Infection Risk Varies by Lupus Nephritis Induction Therapy
Adverse effects of induction therapies for lupus nephritis may limit their use.
Medications
Colchicine May Lower Risk of CKD Progression
Colchicine, a plant-derived alkaloid, has a broad range of anti-inflammatory effects that interfere with neutrophil function, according to investigators.
AKI Risk in COVID-19 vs Flu Not Disproportionately Higher With RAASi Use
New study is the first to examine the effect of the use of renin-angiotensin-aldosterone system inhibitors on AKI in COVID-19.
RAASi Dose Reduction, Discontinuation in CKD Common After Hyperkalemia
In a study of patients with CKD and/or heart failure on RAASi therapy, the proportion of patients who received dose reductions or had therapy discontinued after new-onset hyperkalemia increased with hyperkalemia severity.
Daprodustat Possibly an Oral Alternative to ESAs in Incident Dialysis
In a study of incident dialysis patients, the HIF-PHI agent daprodustat demonstrated safety and efficacy similar to that of the ESA darbepoetin alfa.
Oral Tebipenem Effectively Treats Complicated UTI, Pyelonephritis
Tebipenem pivoxil hydrobromide is an orally bioavailable carbapenem with activity against uropathogenic Enterobacterales.
Tacrolimus May Be an Alternative for First-Line Lupus Nephritis Therapy
In a study, the calcineurin inhibitor tacrolimus proved to be noninferior to intravenous cyclophosphamide.
SGLT2 Inhibitors for Diabetes May Protect Against AKI, Increase UTI Risk
Providers need to assess the benefit-risk profile of SGLT2 inhibitors for individual patients, and take steps to avoid unnecessary risks.
ICI-Based Urologic Cancer Therapies Tied to High Adverse Event Rates
Treatment-related adverse events of any grade develop in the majority of patients who receive urologic cancer therapies based on immune checkpoint inhibitors, according to a study.
Refractory Lupus Nephritis Responds to Add-On Tacrolimus
Nephrotoxicity remains a major concern with the use of calcineurin inhibitors.
